Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMS Medical, a developer of treatments for multiple sclerosis, has received a fifth recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.
Subscribe to our email newsletter
The recommendation came following a meeting of the independent data safety monitoring board (DSMB). This was the fifth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial.
The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. The pivotal phase II/III study is now ongoing at trial sites across Canada, the UK, Sweden, Denmark, and The Netherlands.
“We continue to make excellent progress developing MBP8298 on multiple fronts,” said Kevin Giese, president and CEO of BioMS. “We currently have enrolled more than 300 patients in our pivotal phase II/III SPMS (secondary progressive multiple sclerosis) trial and remain on track to achieve full enrolment by year-end.”
BioMS also recently released its financial results for the second quarter of 2006. The results revealed a widening net loss of $9.1 million for the quarter, compared with $3.5 million for the same quarter in 2005. The increased loss was largely due to an increase in the company’s research and development expenditures.